Human immunodeficiency virus type 1 (HIV-1) matrix (MA or p17) polypeptide capable of inducing anti-p17 antibodies that neutralize the proinflammatory activities of the MA protein
New isolated polypeptides of the protein p17 of HIV are described, represented by the formula: NH 2 -X 1 -Gly-X 2 -X 3 -Leu-Asp-X 4 -Trp-Glu-X 5 -Ile-X 6 -Leu-Arg-COOH (SEQ ID NO:1) in which X 1 is an amino acid residue selected from Ser and Arg; X 2 is an amino acid residue selected from Gly, Glu and Ser; X 3 is an amino acid residue selected from Glu, Lys, Asp and Arg; X 4 is an amino acid residue selected from Arg, Ala, Lys, Thr, Ser, Glu, Asp and Gln; X 5 is an amino acid residue selected from Lys, Arg and Ser; and X 6 is an amino acid residue selected from Arg and Gln. These polypeptides, when administered to a subject, are able to evoke anti-p17 neutralizing antibodies and are therefore useful as vaccine or inoculum. Monoclonal and polycolonal anti-p17 antibodies which are able to neutralize the biological activity of this viral protein and to recognize its neutralization epitope in a specific manner are also described.
1. An isolated polypeptide capable of evoking an anti-p17 antibody that inhibits the proinflammatory biological function of HIV p17 protein consisting of an amino acid sequence NH 2 -X 1 -Gly-X 2 -X 3 -Leu-Asp-X 4 -Trp-Glu-X 5 -Ile-X 6 -Leu-Arg-COOH (SEQ ID NO: 1), wherein X 1 is an amino acid residue selected from Ser and Arg, X 2 is an amino acid residue selected from Gly, Glu and Ser; X 3 is an amino acid residue selected from Glu, Lys, Asp and Arg; X 4 is an amino acid residue selected from Arg, Ala, Lys, Thr, Ser, Glu, Asp and Gln; X 5 is an amino acid residue selected from Lys, Arg and Ser; and X 6 is an amino acid residue selected from Arg and Gln.
2. A polypeptide according to claim 1 , in which said amino acid sequence is NH 2 -Ser-Gly-Gly-Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile-Arg-Leu-Arg-COOH (SEQ ID NO: 2).
3. A polypeptide according to claim 1 , in which a second amino acid sequence capable of increasing the solubility of the polypeptide is directly bound to the amino acid residue in the carboxyterminal position of SEQ ID NO:1 or SEQ ID NO: 2.
4. A polypeptide according to claim 3 , in which the second amino acid sequence is -Pro-Gly-Gly-Lys-Lys-Lys-Tyr-Lys-COOH (SEQ ID NO:3).
5. A polypeptide according to claim 1 , which is conjugated with a carrier.
6. A polypeptide according to claim 5 , which is conjugated with a carrier through an additional residue of cysteine (Cys) or an additional dipeptide -Nleu-Cys in the carboxyterminal position.
7. A polypeptide according to claim 1 , which is in the form of a branched peptide.
8. An immunogenic composition comprising a polypeptide according to claim 1 and a pharmaceutically acceptable vehicle.